Bio-Rad signs deal with DiaMed:
This article was originally published in Clinica
Executive Summary
Life science research and clinical diagnostics specialist Bio-Rad last week signed a definitive agreement to acquire 77.7% of shares in DiaMed, a Swiss test system manufacturer. The agreement will see Bio-Rad pay SFr477m ($389m) in cash for the shares; DiaMed will retain 9.6% of its stock as treasury shares, while Bio-Rad will offer to purchase the remaining 12.7% after the initial deal has been closed later this year. Bio-Rad (Hercules, California) will inherit from DiaMed a comprehensive line of reagents and instruments, used in blood typing and screening, which generated annual revenues of approximately $200m from sales to hospitals, clinical labs and blood banks in over 100 countries.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.